Comparative Effectiveness of Long-Acting Lipoglycopeptides vs Standard-of-Care Antibiotics in Serious Bacterial Infections
JAMA Network Open · 21.05.2025 · 8 (5) · e2511641
DOI: 10.1001/jamanetworkopen.2025.11641 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift JAMA Network Open, online erschienen am 21.05.2025. Verfasst von David Goodman-Meza und 7 weiteren Autor:innen. Beteiligte Einrichtung: Kirby Institute, University of New South Wales Sydney, Sydney, Australia. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Lipoglycopeptides, Teicoplanin, Bacterial Infections. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, NIMH NIH HHS.
Abstract (Originalsprache)
Importance Serious bacterial infections such as bacteremia, endocarditis, osteomyelitis, and septic arthritis typically require prolonged intravenous antibiotics. Long-acting lipoglycopeptides (laLGPs), such as dalbavancin and oritavancin, offer extended treatment intervals for gram-positive infections that may benefit populations with barriers to traditional treatment, including persons who use drugs (PWUD individuals).
Objective
To assess the effectiveness of laLGPs in managing serious bacterial infections in both PWUD and non-PWUD populations compared with standard-of-care (SOC) antibiotics. Design, Setting, and Participants This comparative effectiveness study using a target trial emulation framework included data extracted from the US Cerner Real World Data platform. Individuals hospitalized and discharged for serious bacterial infections between October 1, 2015, and October 1, 2022, were included in the analysis. Data were analyzed from July 7, 2023, to February 28, 2025.
Intervention
Receipt of an laLGP (dalbavancin or oritavancin) vs SOC antibiotics. Main Outcome and Measures The primary outcome measure was a composite of readmission, emergency department visit, and inpatient death or discharge to hospice within 90 days post discharge from the index admission. Analyses were stratified by PWUD and non-PWUD status. Clone censor weighting was used to emulate a per-protocol analysis. Hazard ratios (HR) of time to the composite event and 95% CIs were calculated using bootstrapping.
Results
Among 42 067 included individuals, median age was 61 (IQR, 47-73) years, 24 704 were male (58.7%), and 5047 (12.0%) were classified as PWUD. laLGPs were prescribed in 825 individuals (2.0%). There was no statistically significant difference in the composite outcome between the laLGP and SOC groups in both the PWUD (HR, 1.01; 95% CI, 0.88-1.13) and non-PWUD (HR, 0.93; 95% CI, 0.86-1.00) participants. Conclusions and Relevance In this study of laLGPs vs SOC, findings suggested that laLGPs were effective as step-down treatment of serious gram-positive bacterial infections, offering comparable outcomes to those of SOC antibiotics in PWUD and non-PWUD individuals. Clinicians may consider laLGPs as alternative step-down options to SOC antibiotics for the treatment of serious gram-positive bacterial infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Kirby Institute, University of New South Wales Sydney, Sydney, Australia.
- Division of Infectious Diseases, David Geffen School of Medicine at UCLA (University of California, Los Angeles), Los Angeles.
- UCLA Center for HIV Identification, Prevention, and Treatment Services, Los Angeles.
- Department of Biostatistics, Fielding School of Public Health, UCLA, Los Angeles.
- Medical Imaging Informatics Group, Department of Radiological Sciences, UCLA, Los Angeles.
Förderung
- NIDA NIH HHS
- NIMH NIH HHS
Zitieren
APA
Goodman-Meza, D., Weiss, R. E., Poimboeuf, M. L., Feng, J., Vijayan, T., Martinello, M., Matthews, G. V., & Dore, G. J. (2025). Comparative Effectiveness of Long-Acting Lipoglycopeptides vs Standard-of-Care Antibiotics in Serious Bacterial Infections. JAMA Network Open, 8(5), e2511641. https://doi.org/10.1001/jamanetworkopen.2025.11641
Vancouver
Goodman-Meza D, Weiss RE, Poimboeuf ML, Feng J, Vijayan T, Martinello M, et al. Comparative Effectiveness of Long-Acting Lipoglycopeptides vs Standard-of-Care Antibiotics in Serious Bacterial Infections. JAMA Network Open. 2025;8(5):e2511641. doi:10.1001/jamanetworkopen.2025.11641
BibTeX
@article{GoodmanMeza2025,
author = {Goodman-Meza, David and Weiss, Robert E and Poimboeuf, Michelle L and Feng, Jeffrey and Vijayan, Tara and Martinello, Marianne and Matthews, Gail V and Dore, Gregory J},
title = {Comparative Effectiveness of Long-Acting Lipoglycopeptides vs Standard-of-Care Antibiotics in Serious Bacterial Infections},
journal = {JAMA Network Open},
year = {2025},
volume = {8},
number = {5},
pages = {e2511641},
doi = {10.1001/jamanetworkopen.2025.11641}
}
EUVIMED